• Participant has a diagnosis of chronic plaque psoriasis for \>=6 months prior to the screening visit.

• Participant has stable plaque psoriasis, defined as no significant flare or change in morphology (as assessed by the investigator) in psoriasis, for \>=6 months before screening.

• Participant has moderate-to-severe plaque psoriasis, as defined by a PASI score \>=12 and an sPGA score \>=3, at screening and Day 1.

• Participant has plaque psoriasis covering \>=10 percent (%) of his or her total body surface area (BSA) at screening and Day 1.

• Participant must be a candidate for phototherapy or systemic therapy.